Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Praziquantel.

Donato Cioli1, Livia Pica-Mattoccia

  • 1Institute of Cell Biology, C.N.R., 32 Via Ramarini, 00016 Monterotondo (RM), Italy. dcioli@ibc.rm.cnr.it

Parasitology Research
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

Praziquantel is the primary treatment for schistosomiasis, but its effectiveness against recent infections is limited. Emerging drug resistance in schistosome parasites is a growing concern for physicians.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy.

The Journal of biological chemistry·2017
Same author

Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine.

PLoS neglected tropical diseases·2015
Same author

Schistosomiasis control: praziquantel forever?

Molecular and biochemical parasitology·2014
Same author

Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites.

Science (New York, N.Y.)·2013
Same author

Decades down the line: the viability of praziquantel for future schistosomiasis treatment.

Expert review of anti-infective therapy·2012
Same author

Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis.

Bioorganic & medicinal chemistry letters·2012
Same journal

Two key Actinomycetota taxa in the human gut microbiota are associated with Schistosoma mansoni infection burden.

Parasitology research·2026
Same journal

Gastrointestinal parasites circulating in wild boars from central Italy and molecular characterization of Balantioides coli, Blastocystis sp. and Enterocytozoon bieneusi.

Parasitology research·2026
Same journal

G6PD deficiency and the exportome of plasmodium falciparum FCB-2: a comparative analysis utilizing one-dimensional blue-native electrophoresis and timstof mass spectrometry.

Parasitology research·2026
Same journal

First record of the parasite fauna of Serrasalmus geryi Jegú & Santos, 1988 (Characiformes: Serrasalmidae) and ecological implications of its invasion in a Neotropical floodplain.

Parasitology research·2026
Same journal

Molecular detection of Toxoplasma gondii in marine fish from Tunisia: First report in the Southern Mediterranean Sea.

Parasitology research·2026
Same journal

Identification and multi-omics analysis of extracellular vesicles from the plerocercoids of Spirometra mansoni (Cestoda: Diphyllobothriidae).

Parasitology research·2026
See all related articles

Area of Science:

  • Medical Parasitology
  • Pharmacology
  • Tropical Medicine

Background:

  • Schistosomiasis remains a significant global health burden, necessitating effective chemotherapeutic agents.
  • Praziquantel is the current gold standard treatment for all schistosome infections.

Purpose of the Study:

  • To provide a comprehensive overview of praziquantel for practicing physicians.
  • To analyze praziquantel's pharmacokinetics, efficacy, safety, and potential for drug resistance.

Main Methods:

  • This is a review article, synthesizing existing literature on praziquantel.
  • Key aspects covered include drug history, chemistry, brands, cost, dosing, pharmacokinetics, and drug interactions.

Main Results:

Related Experiment Videos

  • Praziquantel exhibits low toxicity and mild side effects.
  • Efficacy is reduced in recent infections, potentially leading to lower cure rates in endemic areas.
  • Decreased sensitivity of schistosome isolates to praziquantel has been reported.

    • Conclusions:

    • Praziquantel remains the drug of choice despite limitations in treating recent infections.
    • The potential emergence of praziquantel resistance requires ongoing monitoring and research.